Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 2/20 | 0.37 |
| ▸ | MLYCD | O95822 | 2/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15144973 | 0.86 | MLYCD (0.31) | MLYCD | |
| SCHEMBL24958868 | 0.84 | MLYCD (0.31) | MLYCD | |
| SCHEMBL26151827 | 0.82 | MLYCD (0.35) | FFAR2MLYCDTRPM5 | |
| SCHEMBL20642518 | 0.81 | — | — | |
| SCHEMBL1694573 | 0.81 | — | — | |
| SCHEMBL21843830 | 0.80 | MLYCD (0.34) | FFAR2MLYCD | |
| SCHEMBL14417044 | 0.79 | MLYCD (0.40) | MLYCD | |
| SCHEMBL22824966 | 0.79 | — | — | |
| SCHEMBL17148530 | 0.78 | PSEN1 (0.35) | MLYCD | |
| SCHEMBL15166340 | 0.77 | MLYCD (0.32) | FFAR2MLYCDTRPM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348456-A1 | QUINAZOLINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-11-02 | — | — | US | disclosed |
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| WO-2023108108-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| WO-2023076983-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-11566001-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11014881-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20120108585-A1 | BENZOXAZOLES, BENZTHIAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110319411-A1 | ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTIS PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110263564-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-8026264-B2 | Triazole derivatives as inhibitors of 11-β hydroxysteroid dehydrogenase-1 | MERCK SHARP AND DOHME CORP. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566001-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | FFAR2 3555/4885MLYCD 3482/4885CSF1R 3260/4885 |
| US-20110263564-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT6 | FFAR2 2428/4885MLYCD 341/4885CSF1R 1615/4885 |
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | FFAR2 78/4885MLYCD 1403/4885CSF1R 897/4885 |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | FFAR2 4065/4885MLYCD 2912/4885CSF1R 2765/4885 |
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | FFAR2 2228/4885MLYCD 223/4885CSF1R 2166/4885 |
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | FFAR2 3944/4885MLYCD 292/4885CSF1R 1347/4885 |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | FFAR2 2549/4885MLYCD 217/4885CSF1R 906/4885 |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | PIR, CYP3A43, CYP1A2 | FFAR2 4371/4885MLYCD 3694/4885CSF1R 1171/4885 |
| US-11014881-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | FFAR2 3555/4885MLYCD 3482/4885CSF1R 3260/4885 |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | FFAR2 2913/4885MLYCD 288/4885CSF1R 995/4885 |
| US-20230348456-A1 | QUINAZOLINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | CSNK1A1, CSNK1G1, CSNK1G3 | FFAR2 4718/4885MLYCD 2678/4885CSF1R 2438/4885 |
| US-20120108585-A1 | BENZOXAZOLES, BENZTHIAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | FFAR2 2414/4885MLYCD 349/4885CSF1R 1157/4885 |
| US-20110319411-A1 | ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | FFAR2 2464/4885MLYCD 195/4885CSF1R 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.